Diagnostics chains at inflexion point: Emkay
"With competitive intensity reducing after the emergence of the new normal post-pandemic, we believe Indian organised diagnostics chains stand at the cusp of inflexion," said the firm's analysts Anshul Agrawal and Eshan Bhargava in a client note."
Mumbai: Brokerage initiated coverage on diagnostic chains with on and while giving an 'add' rating on ."With reducing after the emergence of the new normal post-pandemic, we believe Indian stand at the cusp of inflexion," said the firm's analysts Anshul Agrawal and Eshan Bhargava in a client note."
"Additionally, tempered expectations following the significant run-up during the pandemic now present investors with an unassailable opportunity to participate in the burgeoning via organised diagnostics chains."
AgenciesThe price targets set by Emkay imply a 20% upside for and 24% for Metropolis.
"Diagnostics chains offer quick scalability and higher profitability, and are in nature, thereby commanding higher multiples versus larger peer hospitals," said the analysts.
Source: Stocks-Markets-Economic Times
